Hims & Hers Health, Inc. (NYSE: HIMS) has officially entered a new chapter in men’s hormone health, launching a category focused on low testosterone treatments designed to be more accessible, affordable, and personalized. With millions of men in the United States experiencing low testosterone—a condition often linked to fatigue, mood changes, sexual health challenges, and increased risk of heart disease, diabetes, and cancer—this initiative addresses a significant unmet medical need.
Why Low Testosterone Treatments Matter
According to Hims & Hers, nearly twenty million men in the U.S. currently face low testosterone, commonly known as “low T.” The condition not only affects day-to-day energy and sexual desire but is also associated with risks such as heart disease, diabetes, and weakened bone and muscle strength.
Testosterone therapy has long been recognized as a way to restore energy, improve libido, enhance muscle mass, and support long-term health. Yet many men go untreated due to stigma, outdated therapies, limited access to specialists, and high costs. By introducing low testosterone treatments, Hims & Hers aims to reduce these barriers and bring men’s hormone health treatments into the digital era. Clinical practice guidelines such as those from the Endocrine Society reinforce the importance of having both symptoms and confirmed low testosterone before starting treatment. Endocrine Society
Partnership with Marius Pharmaceuticals
A key highlight of this initiative is Hims & Hers’ collaboration with Marius Pharmaceuticals to introduce KYZATREX®, an FDA-approved oral testosterone therapy that represents a newer form of testosterone therapy. Slated for release in 2026, this testosterone replacement therapy offers men a needle-free alternative to traditional injections or gels.
Clinical research has shown that KYZATREX can restore testosterone levels in up to 96% of men while doubling free testosterone levels—the form most directly linked to energy, strength, and performance. Importantly, the medication maintains a favorable safety profile, minimizing side effects compared to older therapies.
Andrew Dudum, CEO of Hims & Hers, emphasized the importance of this step: “Low testosterone care has been stuck in the past—stigmatized, expensive, and inaccessible. We’re bringing it into the future with treatments that are easy to access and designed around each individual.”
Shalin Y. Shah, CEO of Marius Pharmaceuticals, added that KYZATREX represents a modernization of testosterone therapy, backed by robust clinical research and FDA approval. The partnership leverages Hims & Hers’ extensive digital health platform to make this treatment available to millions of men nationwide.
Expanding Hormone Health Options
In addition to KYZATREX, Hims & Hers has already made low testosterone treatments available through its platform. Patients now have access to compounded enclomiphene, a therapy that stimulates the body’s natural testosterone production without affecting fertility. Clinical studies on enclomiphene show that it can effectively double testosterone levels, offering men a safe and effective alternative.
For those experiencing sexual symptoms, Hims & Hers is also offering a combination therapy of enclomiphene and tadalafil, providing dual benefits for both hormone balance and sexual function. Looking ahead, the company plans to launch injectable testosterone treatments in 2026, ensuring patients can choose from a full spectrum of low T treatment options.
Personalized, Accessible Care
The Hims & Hers platform is designed to simplify access to men’s hormone health treatments. Patients begin with an at-home blood test , with results available in just a few days. From there, licensed providers develop customized care plans and offering ongoing support through the platform’s digital tools.
This telehealth approach removes many traditional barriers to low testosterone treatment, making it easier for men to seek care privately, affordably, and on their own terms. By providing continuous access to healthcare professionals, Hims & Hers ensures men receive safe, evidence-based treatment without unnecessary delays or costs. The launch of this low testosterone treatment category comes as Hims & Hers continues to expand into other areas of longevity.
